{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-25-000002","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2025-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.742608+00:00","generated_at":"2026-05-28T01:37:03.260070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11","bullets":["Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.","Full year 2024 preliminary revenue $836-838M (+11% YoY); GAAP loss $(1.66)-(1.56)/share; adj EPS $0.14-$0.15.","Cash and equivalents $102M as of Dec 31, 2024, up $2M from Q3.","FY2025 guidance: revenue $840-860M (0-3% growth); adj EPS $0.07-$0.11; adj EBITDA $25-35M.","FY2025 guidance reflects impact from UnitedHealthcare coverage changes and EndoPredict divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-25-000002","json":"https://secwatch.observer/filing/0000899923-25-000002.json","markdown":"https://secwatch.observer/filing/0000899923-25-000002.md","text":"https://secwatch.observer/filing/0000899923-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000002/0000899923-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000002/mygn-20250115.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T01:37:03.260070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}